Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.

Background: Chronic cough is a common reason for medical referral and its prevalence is on the rise. With only one pharmaceutical therapy currently under review for the treatment of refractory chronic ...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.

At the moment there are no approved therapies for suppressing refractory chronic cough, defined as lasting for eight weeks or more, which is estimated to affect somewhere between 5% and 10% of ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Learn the real causes behind uncontrollable coughing and discover effective treatments from medical experts, plus warning ...

While unfortunately, the same state's Department of Health reports their flu rates have reportedly increased 90% week-over-week.

In 2022, chronic lower respiratory disease was the sixth highest cause of death in the U.S., according to results published ...

If your cold symptoms won't quit, you may have something else. Doctors explain what it could mean if you've got a lingering ...

Several risk tools can accurately predict individual baseline risks of adverse events in people with chronic kidney disease. Here, the authors examine methods of assessing risk and discuss risk ...

After hours: February 7 at 5:13:46 PM EST Loading Chart for TRVI ...